We have advised Palatine Private Equity on the acquisition of a significant minority stake in tranScrip.
Based in the Thames Valley, with bases in Dublin, US, Ghana, Hong Kong and Australia, tranScrip provides specialist professional services to pharma companies. The company focuses on the innovation and commercialisation of new medicines. Over the past 12 months, tranScrip has focused heavily on COVID-19, where it leads and supports several innovative antiviral treatment programmes.
The investment is the seventh to be made from Palatine’s £100m Impact Fund, which is dedicated to backing profitable businesses making a positive impact on the environment or society. The money will help tranScrip expand their unique services to reach more organisations worldwide.
Corporate partner, Beth Mather, who led a multi-disciplinary Gateley team on the deal, commented: “With the backing of Palatine, tranScrip will be able to grow its already successful business and potentially add to its service lines through future bolt-on acquisitions. I wish the management team, Palatine and all the staff at tranScrip every success for the future.”